Global Oral Erectile Dysfunction Therapeutics Market Size, Share and Trends Analysis Report, By Drug Type (Sildenafil, Vardenafil, Tadalafil, Avanafil, Udenafil, and Others) Forecast (2022-2028)

The global oral erectile dysfunction therapeutic market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Erectile dysfunction is the inability to maintain a penile erection enough during intercourse. It is one of the most common sexual disorders in males. The oral erectile dysfunction therapeutic market is growing due to the increasing prevalence of high cholesterol, blood pressure, obesity, smoking, and tobacco consumption, as these factors increase the chances of having erectile dysfunction. According to a survey conducted by World Health Organization in December 2019, around 1.3 billion people intakes tobacco globally. The market is also growing due to the rising prevalence of stress and depression among individuals. According to Mental Health Foundation 2018, an estimation of 74% of people globally has felt so stressed they have been overwhelmed or unable to cope. Erectile dysfunction is growing very rapidly in the past few years. According to Massachusetts Male Aging Study, it is estimated that erectile dysfunction affects one-third of the global men population. It also states that some form of erectile dysfunction affects around 52% of men. According to the Journal of Sexual Medicine, it has been found that erectile dysfunction affects about 26% of men under the age of 40.

The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-

  • in January 2022, Petros Pharmaceuticals, Inc. initiated two self-selection studies for its erectile dysfunction drug STENDRA avanafil. The results of these studies will be part of a more comprehensive data package the company plans to submit to the FDA.
  • In November 2021, University Hospitals published Men with erectile dysfunction caused by blockages in the arteries that supply the penis vasculogenic erectile dysfunction has access to a new, relatively uncommon treatment option at University Hospitals Cleveland Medical Center in collaboration with University Hospitals Urology Institute.
  • In January 2020, Roman announced their partnership with Pfizer, Inc. which will allow the digital health firm to source all of the generic Viagra or sildenafil citrate to sell directly from Pfizer.
  • In March 2019, Dr. Reddy’s Laboratories Ltd. announced their launch of Tadalafil tablets that will be used to treat erectile dysfunction in the US market.

Market Coverage

  • The market number available for – 2022-2028
  • Base year- 2021
  • Forecast period- 2022-2028
  • Segment Covered-
    • By  Drug Type
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Competitive Landscape- Petros Pharmaceuticals, Inc., Reddy’s Laboratories Ltd., and Pfizer, Inc., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?
    • Deviation from the pre-COVID-19 forecast
    • Most affected region and segment
  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Oral Erectile Dysfunction Therapeutic Market Report by Segment

By Drug Type

  • Sildenafil
  • Vardenafil
  • Tadalafil
  • Avanafil
  • Udenafil
  • Others

By Application

  • Hospitals
  • Clinics
  • Cancer Research Institutes

Global Oral Erectile Dysfunction Therapeutic Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

The report will be delivered within 48-72 hours after payment confirmation